van der Linden 2017.

Trial name or title	Topical 5% imiquimod cream for vulva Paget's disease: clinical efficacy, safety and immunological response
Methods	Interventional open‐label Phase 3 trial
Participants	Women aged ≥ 18 years with non‐invasive vulval Paget's disease, primary or recurrence after earlier surgery.
Interventions	Imiquimod topical 5% imiquimod cream (Aldara) 3 times a week for 16 weeks Paracetamol Lidocaine in Vaseline ointment
Outcomes	Clinical response will be assessed by vulval examination and measurement and defined as complete remission, partial remission (decrease by ≥ 50% of total lesion size) or no remission.
Starting date	May 2015
Contact information	Joanne A de Hullu, MD, PhD; University Medical Center Nijmegen, the Netherlands
Notes